Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide
2003

How telomerase activity affects glioma cells' response to temozolomide

publication 10 minutes Evidence: moderate

Author Information

Author(s): Kanzawa T, Germano I M, Kondo Y, Ito H, Kyo S, Kondo S

Primary Institution: Mount Sinai School of Medicine

Hypothesis

The responsiveness of malignant glioma cells to temozolomide is associated with the level of telomerase activity.

Conclusion

Telomerase activity decreases in sensitive glioma cells after treatment with temozolomide, indicating a potential marker for therapeutic efficacy.

Supporting Evidence

  • Temozolomide treatment reduced telomerase activity in sensitive glioma cells.
  • TMZ-resistant cells showed no significant decline in telomerase activity.
  • O6-benzylguanine enhanced the effect of temozolomide in resistant cells.

Takeaway

This study found that glioma cells that respond well to a drug called temozolomide have lower levels of a protein called telomerase, which helps cancer cells grow.

Methodology

The study used various glioma cell lines to assess the relationship between telomerase activity and sensitivity to temozolomide through cell viability assays and telomerase activity assays.

Limitations

The study primarily focused on specific glioma cell lines, which may not represent all types of malignant gliomas.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6601193

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication